Evidence map›Paper›PMID 42180949›Full record

ArticleTranslational cancer research2026

Identification of

Junjun Wang, Xiaorui Li, Biyun Zheng, Zhixin Chen, Fenglin Chen, Xuefen Fang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Junjun Wang *Department of Clinical Laboratory, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Xiaorui Li *School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Biyun ZhengDepartment of Gastroenterology and Fujian Institute of Digestive Disease, Fujian Medical University Union Hospital, Fuzhou, China.
Zhixin ChenDepartment of Gastroenterology and Fujian Institute of Digestive Disease, Fujian Medical University Union Hospital, Fuzhou, China.
Fenglin ChenDepartment of Gastroenterology and Fujian Institute of Digestive Disease, Fujian Medical University Union Hospital, Fuzhou, China.
Xuefen FangDepartment of Gastroenterology and Fujian Institute of Digestive Disease, Fujian Medical University Union Hospital, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accumulating evidence has revealed that the Methods: We utilized several public databases, including GEPIA, UALCAN, The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), International Cancer Genome Consortium (ICGC), Human Protein Atlas (HPA), Kaplan-Meier plotter, cBioPortal, LinkedOmics, Metascape, and Tumor Immune Estimation Resource (TIMER), alongside the Cell database, to conduct bioinformatics analysis and explore the relationships between each Results: Conclusions: Our findings suggest that

Indexed as

diagnostic markerEFNA familyhepatocellular carcinoma (HCC)prognostic biomarkertumor immune microenvironment

Identifiers

PMID42180949
PMCPMC13190871

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.